Indication
Neoplasms by Site
28 clinical trials
37 products
11 drugs
Clinical trial
A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination With Palbociclib (Doublet) and With Palbociclib and Sasanlimab (Triplet) in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-06-01
Product
CarboplatinClinical trial
Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsStatus: Active (not recruiting), Estimated PCD: 2024-08-23
Product
PemetrexedProduct
palbociclibProduct
BLU-451Product
NKT2152Clinical trial
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients With EGFR Mutant Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Product
osimertinibProduct
EO-3021Clinical trial
A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Express CLDN18.2Status: Recruiting, Estimated PCD: 2028-09-01
Product
BLU-945Product
SavolitinibClinical trial
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)Status: Active (not recruiting), Estimated PCD: 2019-08-18
Product
SunitinibProduct
RelatlimabProduct
NivolumabProduct
BMS-986213Clinical trial
A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-09-10
Clinical trial
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion CohortsStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Product
PT-112Product
PralsetinibClinical trial
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-03-21
Clinical trial
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)Status: Recruiting, Estimated PCD: 2026-10-01
Product
STAR0602Clinical trial
Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab MonotherapyStatus: Active (not recruiting), Estimated PCD: 2022-09-07
Product
nivolumabProduct
rHuPH20Clinical trial
A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2022-12-09
Product
carboplatinProduct
pemetrexedProduct
BLU-701Clinical trial
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2022-06-30
Product
nab-PaclitaxelProduct
GemcitabineClinical trial
A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsStatus: Terminated, Estimated PCD: 2022-05-16
Product
AlectinibClinical trial
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Drug
PralsetinibDrug
CisplatinProduct
PembrolizumabDrug
GemcitabineDrug
TiragolumabDrug
Nab-PaclitaxelClinical trial
A Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without RelatlimabStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)Status: Active (not recruiting), Estimated PCD: 2024-08-31
Drug
177Lu-PSMA-617Product
IpilimumabClinical trial
A Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-06-30
Drug
AdebrelimabProduct
Carboplatin/CisplatinProduct
EtoposideDrug
AtezolizumabClinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive CancersStatus: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.Status: Recruiting, Estimated PCD: 2029-10-01
Drug
EntrectinibClinical trial
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm StudyStatus: Active (not recruiting), Estimated PCD: 2022-03-30
Product
CamrelizumabDrug
SOXClinical trial
A Study on the Efficacy, Safety and Cellular Pharmacokinetics of RD13-02 Cell Injection in Patients With Relapsed or Refractory CD7-positive Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2025-02-20
Product
RD13-02Clinical trial
A Study for Safety, Efficacy and Cellular Pharmacokinetics of CD7 CAR-T Cell for Patients With Relapsed or Refractory CD7 Positive T-cell Acute Lymphoblastic Leukemia/Lymphoblastic LymphomaStatus: Recruiting, Estimated PCD: 2024-03-20
Clinical trial
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Product
G207Clinical trial
A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
P-PSMA-101 CAR-T cellsProduct
RimiducidClinical trial
High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy or Radical ProstatectomyStatus: Active (not recruiting), Estimated PCD: 2024-02-06
Product
18F-PSMAClinical trial
An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-12-01
Drug
ElacestrantProduct
AbemaciclibClinical trial
A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2025-09-30
Product
AnlotinibProduct
Carboplatin + Paclitaxel